A Billion-Dollar Aldosterone Synthase Inhibitor, an Oral KRASG12D Inhibitor Entering Development, and 14 More Molecules in the News

In this update of small molecules in the news we will cover recent:

  • (B/M)illion-Dollar Molecules: recent M&A’s, IPOs, and other fundraising
  • Molecules in Motion: clinical trial updates and FDA filings
  • Where Are They Now? updates on past Drug Hunter Molecules of the Month
  • Potential Upcoming Approvals: recent NDA filings and upcoming PDUFA dates

Want updates like this straight to your inbox? Sign up for our weekly newsletter here.

Million-Dollar Molecules


This highly selective, oral aldosterone synthase (CYP11B2) inhibitor is being acquired by AstraZeneca via CinCor in a $1.8B transaction. The molecule is in several Ph. II trials (0.5-2 mg QD) for hypertension, CKD, and primary aldosteronism, appears to have demonstrated dose-dependent PK/PD and blood pressure response, and appears to be well-tolerated so far. CinCor licensed the molecule from Roche (RO6836191).

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.

Join Subscribers from

…and hundreds more!